📇 Rhumatologue · LA ROCHELLE · (17) · Libéral

MME Carine CARON

Pourquoi vous devez consulter ce praticien

4 raisons identifiées

Praticien-chercheur
18 articles scientifiques publiés — formation continue solide
Référence presse grand public
Cité 1 fois dans les médias — pédagogie reconnue
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
120.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 LA ROCHELLE (17)LibéralRPPS 10002700572

✨ Génération du profil synthétique IA en cours…

Lieux de consultation(2)

CSAPA TREMPLIN 17 ANTENNE LA ROCHELLE
13 R FRANC LAPEYRE, 17000 LA ROCHELLE
☎ 0546984720Activité de soin et de pharmacie
CABINET DU DR CARINE CARON
3 RUE THIERS, 17100 SAINTES
☎ 0546925510Activité de soin et de pharmacie

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants

Thrombosis and haemostasis · 1995

📚 191 citations🎯 RCR 7.26Top 4% NIH

Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity

Lupus · 2017

📚 60 citations🎯 RCR 3.15Top 15% NIH

Lire l'abstract Crossref ↓

Introduction The long-term risk of first thrombosis and benefit of prophylaxis in antiphospholipid antibody (aPL) carriers without history of thrombosis or obstetrical morbidity is poorly known. This study aimed to evaluate the long-term rate and risk factors associated with a first thrombosis in those patients. Patients and methods After a prior study ended in December 2005 and was already published, we extended the follow-up period of our cohort of aPL carriers. Results Ninety-eight of the 103 patients of the previous study were included. The annual first thrombosis rate was 2.3% per patient-year during a median of 13 years (6–17). None of the baseline characteristics was predictive of risk of first thrombosis, but persistent aPL over time were associated with an increased risk. The stronger association was found in triple aPL-positive carriers: OR 3.38 (95% CI: 1.24–9.22). Of note, conversely to our previous findings, no benefit of aspirin prophylaxis was observed. Conclusion The risk of first thrombosis in aPL carriers without history of thrombosis or obstetrical morbidity was significant, persisted linearly over time and was associated with persistent aPL. This risk was especially increased in triple aPL-positive carriers, in whom a close follow-up seems to be necessary. Nevertheless, the benefit of aspirin prophylaxis remained unclear.

Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients

Lupus · 2008

📚 59 citations🎯 RCR 1.97

Lire l'abstract Crossref ↓

One hundred and three consecutive asymptomatic anti-phospholipid (aPL) antibody-positive carriers, taking aspirin ( n = 75) or not ( n = 28), were studied retrospectively to determine whether aspirin could provide primary prevention of anti-phospholipid syndrome (APS) symptoms. All patients positive for anti-cardiolipin antibodies (aCL; >25 UGPL or UMPL) and/or lupus anti-coagulant were followed for a mean of 64 ± 24.7 months. Among aPL-positive patients, 37 had systemic lupus erythematosus (SLE), 20 had prolonged activated partial thromboplastin times, 19 had other connective tissue diseases, 16 had autoimmune thrombocytopenia (AIT), 11 had diverse diseases. Nineteen patients experienced thrombotic event(s) during follow-up. Clinical features, biological parameters and hydroxychloroquine use were comparable for the two groups, but thrombotic events differed (log-rank test; P = 0.02). Four of the 10 SLE patients not taking aspirin developed thrombosis compared with 3/27 SLE patients taking aspirin (log-rank test; P = 0.03). Anti-phospholipid -positive patients with AIT developed fewer thromboses while taking aspirin (log-rank test; P = 0.01). In conclusion, aPL-positive SLE and AIT patients should take aspirin to prevent APS manifestations. Prospective therapeutic trials are needed to confirm aspirin's prophylactic role in such patients. Lupus (2008) 17, 11—15.

Cookies & analyse de trafic

MME Carine CARON

Pourquoi vous devez consulter ce praticien

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (1)

Top publications · les plus citées

Publications scientifiques (18) — classées par pathologie

SAPL9

Transversal5

Épidémiologie & registres2

IRM ostéo-articulaire1

Lupus1

Maladie de Horton1

Vascularites des gros vaisseaux1

Partager cette fiche